The use of dianhydrogalactitol provides a novel therapeutic modality for the treatment of non-small-cell lung carcinoma (NSCLC) and ovarian cancer, as well as other types of malignancy, including brain metastases of NSCLC. Dianhydrogalactitol acts as an alkylating agent on DNA that creates N.sup.7 methylation. Dianhydrogalactitol is effective in suppressing the growth of cancer stem cells and is active against tumors that are refractory to temozolomide, cisplatin, and tyrosine kinase inhibitors; the drug acts independently of the MGMT repair mechanism. Dianhydrogalactitol can be used together with other anti-neoplastic agents and can possess additive or super-additive effects.

The use of dianhydrogalactitol provides a novel therapeutic modality for the treatment of non-small-cell lung carcinoma (NSCLC) and ovarian cancer, as well as other types of malignancy, including brain metastases of NSCLC. Dianhydrogalactitol acts as an alkylating agent on DNA that creates N.sup.7 methylation. Dianhydrogalactitol is effective in suppressing the growth of cancer stem cells and is active against tumors that are refractory to temozolomide, cisplatin, and tyrosine kinase inhibitors; the drug acts independently of the MGMT repair mechanism. Dianhydrogalactitol can be used together with other anti-neoplastic agents and can possess additive or super-additive effects.

A room temperature injectable thermo-responsive hydrogel comprises a P407 poloxamer base hydrogel, chitosan, 2-Hydroxypropyl β-cyclodextrin and genipin. The chitosan and genipin form an interpenetrating scaffold within the hydrogel in which the chitosan is crosslinked with genipin. Chemotherapeutic drugs can be added to the hydrogel singly or in combination in effective amounts without any loss of thermo-responsiveness in the hydrogel. Therapeutic use of the thermo-responsive hydrogel in the intratumoural treatment of solid cancer is also described.

A room temperature injectable thermo-responsive hydrogel comprises a P407 poloxamer base hydrogel, chitosan, 2-Hydroxypropyl β-cyclodextrin and genipin. The chitosan and genipin form an interpenetrating scaffold within the hydrogel in which the chitosan is crosslinked with genipin. Chemotherapeutic drugs can be added to the hydrogel singly or in combination in effective amounts without any loss of thermo-responsiveness in the hydrogel. Therapeutic use of the thermo-responsive hydrogel in the intratumoural treatment of solid cancer is also described.

The present invention relates to a formulation providing anti-aging benefits that may include ingredients from various ingredient groups such as amino acids, vitamins or mineral co-factors, antioxidants or carotenoids, an herbal, plant derivative, or phytonutrients, and other nutrients. When combined, these ingredients and, more specifically, the herbal, plant derivative, or phytonutrients blend provide increased and unexpected synergistic effects that inhibit DPP4 activity and provide anti-aging benefits.

The present invention relates to a formulation providing anti-aging benefits that may include ingredients from various ingredient groups such as amino acids, vitamins or mineral co-factors, antioxidants or carotenoids, an herbal, plant derivative, or phytonutrients, and other nutrients. When combined, these ingredients and, more specifically, the herbal, plant derivative, or phytonutrients blend provide increased and unexpected synergistic effects that inhibit DPP4 activity and provide anti-aging benefits.

The present invention relates to a formulation providing anti-aging benefits that may include ingredients from various ingredient groups such as amino acids, vitamins or mineral co-factors, antioxidants or carotenoids, an herbal, plant derivative, or phytonutrients, and other nutrients. When combined, these ingredients and, more specifically, the herbal, plant derivative, or phytonutrients blend provide increased and unexpected synergistic effects that inhibit DPP4 activity and provide anti-aging benefits.

Described herein are compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic. Also described are lyophilized compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic.

Described herein are compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic. Also described are lyophilized compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic.

This disclosure generally relates to methods of treating copper-induced neurological damage observed in copper metabolism-associated diseases or disorders. This disclosure relates to reducing the copper-induced neurological damage in Wilson disease (WD).